Diagnostic performance of multifocal photopic negative response, pattern electroretinogram and optical coherence tomography in glaucoma

Authors and affiliations
Khaldoon O. Al-Nosairey¹, Hagen Thieme¹, Michael B. Hoffmann¹, ²
¹Department of Ophthalmology, Otto-von-Guericke University, Leipziger Str. 44, 39120 Magdeburg, Germany
²Center for Behavioral Brain Sciences, Magdeburg, Germany

Correspondent details:
Michael B. Hoffmann
Department of Ophthalmology, Otto-von-Guericke University, Leipziger Str. 44, 39120 Magdeburg, Germany
Phone: +49 391 67 13585
Fax: +49 391 67 13570
Email: michael.hoffmann@med.ovgu.de

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

Objectives. To optimize stimulation parameters for electroretinographic recordings of the multifocal photopic negative response (mfPhNR) for the detection of glaucoma and to compare the diagnostic accuracy of electrophysiological, structural and functional measures of glaucoma.

Methods. In 24 healthy controls, 10 glaucoma suspects (GLAS) and 16 glaucoma participants (GLAG), mfPhNR for 6 different stimulation rates were assessed to compare their discrimination performance. Subsequently, a cross-modal comparison of the mfPhNR/b-wave ratio was performed with pattern electroretinogram (PERG), and peripapillary retinal nerve fiber layer (pRNFL) thickness. These analyses were based on area under curves (AUC) obtained from receiver-operating-characteristics (ROC) analyses and step-wise regression analyses.

Results. Compared to the other mfPhNR-conditions, the PhNR/b-wave ratio for the fastest stimulation condition had the highest AUC for GLAS (0.84, P = 0.008, 95%CI: 0.71- 0.98); the other modalities, i.e., PERG-amplitude and pRNFL had AUCs of 0.77, and 0.74 respectively. pRNFL was the significant predictor for mfPhNR/b-wave ratio [t (48) = 4, P 0.0002].

Conclusions. Fast mfPhNR protocols outperform other mf-protocols in the identification of glaucomatous damage especially for GLAS and thus aid the early detection of glaucoma.

Significance. mfPhNR recordings might serve as surrogate marker of ganglion cell dysfunction especially in glaucoma suspects.

Keywords: multifocal; ERG; photopic negative response; glaucoma; pattern electroretinogram; retinal ganglion cells;
1. INTRODUCTION

Glaucoma is leading as an irreversible cause of visual impairment (Flaxman et al. 2017) and early detection is of great importance. Several methods are at hand to tap functional and structural damage in glaucoma. Standard automated perimetry (SAP) allows for an assessment of visual function in glaucoma that might be linearly correlated with (Harwerth et al. 2004) or preceded (Quigley et al. 1989; Kerrigan-Baumrind et al. 2000) by structural damage in retina. However, the subjective nature and high variability of SAP might hinder its ability to assess changes in visual function (Chauhan et al. 2008). Electrophysiological measure of vision, on the other hand, is another tool that allows for an objective assessment of visual function.

An important tool for the assessment of retinal ganglion cell function is the steady state pattern electroretinogram (ssPERG) and it can detect glaucoma prior to visual field loss (Bach and Hoffmann 2006, 2008). In fact, previous studies demonstrated that PERG could predict glaucoma conversion of ocular hypertension 4 years before conversion, i.e. before any detectable visual field defects on SAP (Bach et al. 2006; Bode et al. 2011). The full-field ERG (ff-ERG) recorded under light adaptation is another method of particular interest as it provides assessment of inner retinal functions (i.e., ganglion cells) via a component termed the photopic negative response (PhNR) (Viswanathan et al. 1999, 2001). It has the additional benefit, that it is, compared to the PERG, more robust to optic media opacities and refractive errors. PhNRs to full field stimulation do not allow for the detection of focal or localized retinal damage, as the response is the sum response of both healthy and diseased retinal areas (Viswanathan et al. 1999).

Focal PhNRs from multiple retinal areas were reported to detect early functional loss in diseases affecting retinal ganglion cells' functions (Machida et al. 2010). The multifocal stimulation approach introduced by Sutter et al (Sutter and Tran 1992; Sutter 2001) allows obtaining visual field topographies of retinal and cortical function within short time. Therefore, combining PhNR-recordings with the multifocal approach might enhance its scope in identifying retinal ganglion cell dysfunction. In fact, several studies employing PhNRs recorded with adapted multifocal ERG protocols (mfPhNR) were conducted in glaucoma and optic nerve lesions (Kamei and Nagasaka 2010, 2014; Kamei et al. 2011; Rajagopalan et al. 2014; Kaneko et al. 2015; Kato et al. 2015; Tanaka et al. 2020) and regional PhNR-changes were
demonstrated. Different multifocal stimulation modes were used in these studies, i.e., fast (Kamei and Nagasaka 2010, 2014; Kamei et al. 2011; Kaneko et al. 2015; Kato et al. 2015; Tanaka et al. 2020) (1 to 9 interleaved frames) or slow stimulation sequences (Rajagopalan et al. 2014; Van Alstine and Viswanathan 2017) (around 30 interleaved frames). It is not clear at present, whether any of these modes are of specific advantage for the detection of ganglion cell damage. This prompted our present investigation. We aimed (1) to determine which of the slow and fast stimulation modes yields highest mfPhNRs, (2) which condition performs best for the differentiation of controls and glaucoma patients, and (3) how it compares to other established diagnostic methods [i.e., PERG and peripapillary retinal fiber layer thickness (pRNFL)]. We found the fastest mfPhNR-protocol to be the superior multifocal protocol for the discrimination of GLAs.

2. MATERIALS AND METHODS

2.1. Participants

We included 50 participants in the study as detailed below. Participants gave their written consent to participate in the study. The procedures followed the tenets of the declaration of Helsinki and the protocol was approved by the ethical committee of the Otto-von-Guericke University of Magdeburg, Germany. Participants underwent complete ophthalmic examinations and subjective and objective refractions were assessed for both near and far visual acuity to determine best corrected visual acuity (BCVA). Exclusion criteria were any eye diseases or surgeries except cataract and glaucoma surgery, incipient cataract that did not decrease BCVA < 0.8 (Bach and Mathieu 2004) and refractive error exceeding ± 5 D or astigmatism > ± 2 D. There was no significant difference between age across groups [ANOVA, F (2, 48) = 2.7, P = .08]. Demographic and clinical characteristics of each group are shown in Table 1. All glaucoma participants were under either medical and/or surgical treatment.

Controls: Twenty-four participants (mean age ± standard error (SE): 52.1 ± 2.3 years) with normal visual acuity (VA≥1.0) were included in the study. Only left eyes were included for the analysis and all met the inclusion criteria. 1 participant had no PERG and OCT measurements.
Primary open angle glaucoma suspects’ group (GLAs). Left eyes of 10 patients (mean age ± SE: 61.8 ± 1.8 years) were included in the study. All glaucoma suspects’ eyes in our study had an open anterior chamber angle with normal appearance of optic disc and RNFL and either (Prum et al. 2016) (i) a visual field defect suspicious for glaucoma damage (i.e., as defined for GLA_G group below) without any other apparent causes (n=4), or (ii) consistently elevated intraocular pressure (IOP) > 21 mmHg (n=6).

Glaucoma group (GLA_G). Sixteen glaucoma patients (mean age ± SE: 57.90 ± 3.8 years) were included in the study. Ten patients with primary open angle glaucoma, 5 patients with normal tension glaucoma and 1 patient with pigment dispersion glaucoma. Glaucoma severity ranges from preperimetric to severe stages. Eyes with worse glaucoma damage was chosen for the analysis and in one participant, both eyes had different glaucoma damage stages and both were included separately (i.e., 17 eyes were included in the analysis). GLA_G patients met the following criteria (Preiser et al. 2013): 1) Local notching of optic disc rim or vertical cup disc ratio ≥ 7; 2) Visual field defect with 3 or more adjacent points of ≥ 5 dB loss or two or more adjacent points of ≥ 10 dB loss detected in Standard static white-on-white perimetry. Preperimetric glaucoma eyes had no visual field defects.

2.2. Standard automated perimetry

Standard automated perimetry (dG2; dynamic strategy; Goldmann size III; OCTOPUS® Perimeter 101, Haag-Streit International, Switzerland) was tested to the central 30° ofVF.

2.3. SD-OCT

Peripapillary retinal nerve fiber layer thickness (pRNFL) from a 3.5 mm circle scan centered on optic disc (12° diameter) with 768 A-scan Spectral domain optical coherence tomography (OCT) was performed with the OCT Spectralis (Heidelberg Engineering, Heidelberg, Germany).

2.4. Electrophysiological testing

Procedure. Two types of ERG-recordings, mfPhNR and PERG, were applied in separate sessions, for better comparability both at the same viewing distance of 33 cm. Binocular mfPhNR and PERG were recorded using DTL (Dawson, trick Litzkow
1979, Thompson, Drasdo, 1987) electrodes (DTL Electrode ERG, Unimed electrode Supplies, Ltd, UK) placed in the upper margin of lower lid. The reference electrode (10 mm diameter; Golden EEG Cup Electrodes, Natus Manufacturing Limited, Ireland), filled with conductive paste (Ten20, WEAVER and Company, USA), was attached to the temple ipsilateral of the corresponding eye. The ground electrode filled with conductive paste was pasted on the forehead. Reference and ground electrodes were attached after skin cleaning with a cleaning paste (skinPure, NIHON KODEN Corporation, Tokyo, Japan) to reduce the resistance of the skin below 5 kOhm. Pupils were dilated when recording mfPhNR with Tropicamide 0.5% (Mydriaticum Stulln® UD, Pharma Stulln GmbH, Germany) to approximately 7 mm. Corneas were locally anaesthetized with Oxybuprocain hydrochlorid 0.4% (Conjuncain® EDO®, Bausch&Lomb GmbH, Germany). Refractive correction optimized for a viewing distance of 33 cm for both mfPhNR and PERG recordings.

**mfPhNR stimulation, recording and analysis.** The stimulus display covered 48° and comprised 5 visual field locations (Figure 1), a central (0° – 5°) and four adjacent (from 5°-24° eccentricity). The 5 fields of this display were stimulated independently with an m-sequence, a pseudo-random succession of 0 (no flash) and 1 (flash) states. In accordance with previous literature (Van Alstine and Viswanathan 2017), we applied an m-sequence length of 2⁹-1 (511) steps, each step lasted 13.3 ms. This resulted in a total recording ranging from 3 minutes and 23 seconds in the slowest protocol and 1 minute and 1 second in the fastest protocol. The testing protocol was subdivided into 16 segments to allow blinking. Recording segments comprising artifacts, e.g. from eye movements or blinking, were re-recorded. VERIS Science 6.4.9d13 (EDI: Electro-Diagnostic Imaging, Redwood City, CA, USA) was used for stimulus delivery and electrophysiological recordings. For each area in the dartboard, the stimulus consisted of either 1, 2, or 5 bright frames, each occurring on 50% of the frame changes (75 Hz) followed by either 8 or 25 dark frames This resulted in 3 fast conditions, i.e., 8 dark frames, with 1, 2 and 5 bright frames for stimulation (C_Fast_1, C_Fast_2 and C_Fast_3, respectively) and 3 slow conditions, i.e., 25 dark frames, with 1, 2 and 5 bright frames for stimulation (C_Slow_1, C_Slow_2 and C_Slow_3, respectively). The averaged stimulation frequency arising ranged from 1.3-4.2 Hz. Each condition was repeated twice in a counterbalanced sequence of conditions. The luminance of [i] white frames (stimulation), [ii] uniform grey background, and [iii]
black frames (no stimulation) were set at 200, 100, and 7 cd/m², respectively, as checked with a calibrated photometer (CS-100A photometer; Konica Minolta Holdings, Inc.; Japan). Stimuli were presented on a monochrome CRT-monitor (MDG403, Philips; P45 phosphor) at a frame rate of 75 Hz, while the measurement was checked on a separate control monitor.

Using VERIS Science 6.4.9d13, the signals were amplified by 100 K (Grass Model 12, Astro-Med, Inc., West Warwick, RI, USA), band-pass filtered 3-100 Hz and digitized at 1200 Hz. The first order kernels were extracted using VERIS Science 6.4.9d13. Subsequent analyses were performed using Igor (WaveMetrics Inc., Lake Oswego, OR, USA). Traces were then digitally filtered (high pass filter: 3Hz; low pass filter: 45 Hz). Repetitions of each condition were averaged. Traces from right eyes were left-right flipped to match stimulated visual fields of traces recorded from left eyes of other participants.

We determined the amplitudes for the a-wave (1st negativity), b-wave (1st positivity) and the mfPhNR, within a time window of 15 to 35 ms, 20 to 50 ms, and 55 to 90 ms, respectively. For the determination of the latter time window we calculated, following Van Alstine and Viswanathan (Van Alstine and Viswanathan 2017), the waveforms’ grand means for the control group within each age bin and we summed all test location waveforms’ grand means. This resulted in mfPhNRs to peak around 70-75 ms, adding 15 ms allowed to cover the individually varying trace forms. Consequently, mfPhNR amplitude was localized within a time window of 55-90, which is similar to conventional PhNR amplitudes timing described previously (Machida et al. 2015). Following studies of mfPhNR (Kaneko et al. 2015) and full field (conventional) photopic ERG (Machida et al. 2008; Preiser et al. 2013), the PhNR amplitude was also evaluated in respect to b-wave measured from baseline (PhNR/b-wave ratio). Before normalizing mfPhNR to the b-wave, we first assessed the b-wave between groups. We found no significant differences of neither b-waves amplitudes nor peak times of all conditions across groups upon one-way ANOVA testing. All amplitudes were measured from trough to baseline. For an assessment of the visual field topography, we performed analyses for different groups of the stimulated visual field locations: We summed all visual field locations to represent the summed visual field locations response (VFSUM), summed the pairs of visual field patches to cover four different visual field locations, i.e., upper, lower,
nasal and temporal hemifields and periphery), and assessed the central response in isolation.

**PERG stimulation, recording and analysis.** Steady state PERGs were recorded following the international society for clinical electrophysiology of vision (ISCEV) standards for PERG recordings using EP2000 evoked potential system(Bach). By subtending an angle of 62°x49°, the stimulus was presented on 21-inch monochrome monitor with a 75 Hz frame rate (MDG403, Philips; P45 phosphor). Contrast-inverting (15 Hz) checkerboard patterns (mean luminance: 45 cd/m^2; contrast: 98%) with two checksizes, 0.8° and 15° were presented for stimulation at a viewing distance of 33 cm, as for the mfPhNR measurements. Signals exceeding ± 90 µV were rejected and recollected. Two PERG blocks were recorded and averaged per subject. Only PERG 0.8° amplitude and PERG ratio (small/big checksizes’ amplitudes) were used for analysis. Further description of analysis is mentioned elsewhere(Bach and Hoffmann 2008; Preiser et al. 2013; Al-Nosairy et al. 2020).

**2.5. Statistics**

mfPhNR responses and PERG amplitudes were transferred into Igor sheet and exported to SPSS 26 (statistical Package for the Social Sciences, IBM) or the R statistical system(R Core Team (2013)). Repeated measure analysis of variance (RM-ANOVA), analysis of variance (ANOVA), receiver operating characteristics analysis (ROC) and Post-hoc analysis were run between groups and protocols using SPSS 26 and R. P values were corrected with the Holm Bonferroni correction(Holm 1979) for multiple testing. Pairwise comparisons of two AUCs were conducted to assess whether there is a significant difference by calculating a critical ratio $z$ using the following formula(Hanley and McNeil 1983):

$$z = \frac{\text{Area}_1 - \text{Area}_2}{\sqrt{SE_{\text{Area}_1}^2 + SE_{\text{Area}_2}^2 - 2r(SE_{\text{Area}_1})(SE_{\text{Area}_2})}}$$

and unpaired comparison of AUCs from 2 different data sets (controls vs GLAs and Controls vs GLA_G) were done using the following formula(Motulsky):

$$z = \frac{|\text{Area}_1 - \text{Area}_2|}{\sqrt{SE_{\text{Area}_1}^2 + SE_{\text{Area}_2}^2}}$$
Where \( A_1 \) and \( A_2 \) refers to area under curve with their respective standard error (\( SE_1 \) & \( SE_2 \), respectively) for method 1 and 2, respectively, and \( r \) represents estimated correlation between \( A_1 \) and \( A_2 \). \( Z \) value is referred to the normal distribution tables and \( z \) value \( \geq 1.96 \) means there is a true difference between both AUCs.

3. RESULTS

3.1. Comparison of mfPhNR recording protocols

Multifocal stimulation settings that were previously applied for mfPhNR recordings ranged between fast (1-9 frames; Kamei and Nagasaka 2010, 2014; Kamei et al. 2011; Kaneko et al. 2015; Kato et al. 2015; Tanaka et al. 2020) and slow (30 frames; Rajagopalan et al. 2014; Van Alstine and Viswanathan 2017) sequences. In a first step, we performed a quantitative comparison of these settings and their transitions in order to identify the most effective stimulation condition. This condition subsequently entered the second step, i.e., a detailed analysis of the parameters determining the diagnostic potential.

Comparison of stimulation conditions. For an initial characterization of the mfPhNR for the different conditions, we compared response amplitudes between the different conditions for the controls. This was followed by an analysis of the discrimination performance and efficacy in the detection of glaucoma-related damage. We applied six different stimulation settings for mfPhNR recordings and compared the mfPhNR amplitude and mfPhNR/b-wave ratio as detailed in Methods for the control group. A one-way repeated measure ANOVA [factor, \( \text{condition} \) (\( C_{\text{Slow,}3} \) to \( C_{\text{Fast,}1} \))] was conducted to determine the effect on mfPhNR amplitude and mfPhNR/b-wave ratio of the summed visual field locations' response (\( \text{VF}_{\text{SUM}} \)). There was a significant effect of condition on both mfPhNR amplitude [\( F (2.2, 51.7) = 4.3, \) \( P = 0.015 \)] and mfPhNR/b-wave ratio [\( F (1.7, 38.8) = 12.6, \) \( P = 0.0001 \)]. Post-hoc analyses were initially performed for the two most widely used conditions (\( C_{\text{Fast,}1} \) vs \( C_{\text{Slow,}1} \) and demonstrated both mfPhNR amplitude and mfPhNR/b-wave ratio to be significantly lower for \( C_{\text{Fast,}1} \) [\( t (23) = 3.8 \) and -5.8, \( P = 0.001 \) and 0.00002, respectively]. Comparing \( C_{\text{Fast,}1} \) to the other conditions, mfPhNR-amplitudes were significantly lower than for \( C_{\text{Slow,}2} \) (\( P = 0.004 \)), while mfPhNR/b-wave ratios were significantly lower than for all other conditions (see Table 2 for effect sizes). While amplitudes are informative to characterize the responses obtained for different
stimulation conditions, an assessment of the discrimination performance between controls vs GLAS and GLAG is instrumental to identify the condition with the highest diagnostic power. Therefore, we conducted ROC analyses and used the area under curve (AUC) as a measure of the diagnostic performance for each condition for both mfPhNR amplitude and mfPhNR/b-wave ratio as depicted in Figure 2. For most conditions, the ROC analyses yielded similar AUCs. Pairwise AUC-comparisons (see Methods), identified only the CFast_1 for the mfPhNR/b-wave ratio to be significantly higher than the CSlow_1 in discriminating controls vs GLAS, i.e. AUC ± SE: 0.84 ± 0.07 vs 0.59 ± 0.1, respectively (P = 0.02). In summary, CFast_1 had the highest discrimination performance, albeit not having the highest amplitudes and therefore entered the subsequent detailed analysis.

3.2. Trace characteristics and topographical analysis for the CFast_1 protocol

Typical ERG trace shapes were obtained for all participant groups (controls, GLAS, and GLAG, see Figure 3) with a negativity, positivity and negativity, termed, in accordance with the current literature\(^21\), a-wave, b-wave, and PhNR, respectively. No significant group effects were observed for peak time and amplitude of a- and b-waves, neither for the responses of each of the five visual field locations, nor for the summed response, i.e., VF\text{SUM}. In contrast, both the mfPhNR VF\text{SUM} amplitude and the mfPhNR/b-wave VF\text{SUM} ratio were reduced in the patients groups (GLAS and GLAG) compared to controls upon ANOVA testing [mfPhNR VF\text{SUM} amplitude: F (2, 48) = 5.7, P = 0.018; mfPhNR/b-wave VF\text{SUM} ratio: F (2, 48) = 9.8, P < 0.007 = 0.00027]. For subsequent analyses, we focused in accordance to previous studies, on mfPhNR/b-wave ratio of VF\text{SUM} response. Finally, no significant group effects were observed for mfPhNR VF\text{SUM} peak times [F (2, 48) = 2.9, P ≥ 0.06].

To assess whether the effects differed for specific hemifields and eccentricities, we subdivided the four peripheral visual field locations into upper, lower, nasal and temporal hemifields and center and periphery. As depicted in Figure 4, in both GLAS and GLAG vs Controls the mfPhNR/b-wave ratio was significantly reduced for all sub-regions analyzed, except the center. The mfPhNR/b wave ratio of the VF\text{SUM} response was also significantly different between in both GLAS and GLAG vs Controls upon ANOVA testing [F (2, 48) = 9.8, P < 0.007 = 0.00027] as detailed in Figure 4.G.
3.3. Cross-modal comparison of glaucoma-related damage

We were particularly interested to determine the diagnostic accuracy of our measure, the mfPhNR/b-wave ratio of C_{Fast-1}, in comparison to other established diagnostic methods, i.e. PERG or pRNFL. Therefore, we conducted ROC analyses and determined the AUCs (± SE) for mfPhNR/b-wave ratio, PERG .8° amplitude and PERG ratio and pRNFL (Figure 5.A). In GLA_s, inspection of Figure 5.A suggested that mfPhNR/b-wave ratio was the measure with highest AUC, but statistical testing did not reveal a significant difference between modalities. In GLA_G, the highest AUC was reached for pRNFL, but without statistically significant differences from other measures. It is noteworthy that all our diagnostic measures showed no AUC difference between Controls vs GLA_s and Controls vs GLA_G based on unpaired AUC comparison.

Subsequently, we compared the functional and structural parameters between both groups applying a one-way ANOVA and post-hoc analyses to compare each patient group vs controls. The mfPhNR/b-wave ratio differed significantly between controls, GLA_s and GLA_G (P<0.025 = 0.00027). Post-hoc tests (Figure 5.B) showed that mfPhNR/b-wave ratio were significantly reduced in GLA_s and GLA_G vs controls (T-test; P<0.025 = 0.00118, P<0.05 = 0.00119, respectively). Both PERG 0.8° amplitude and PERG ratio differed also significantly between controls and patient groups (ANOVA; P<0.0166 = 0.00008 and P<0.05 = 0.03, respectively; Figure 5.C/D). In GLA_s, PERG 0.8° amplitude and PERG ratio were significantly reduced compared to controls (T-test; P<0.05 = 0.015 and P<0.025 = 0.013, respectively). In GLA_G, PERG 0.8° amplitude and PERG ratio were significantly reduced compared to controls (T-test; P<0.025 = 0.00005 and P<0.05 = 0.045, respectively). Since PERG 0.8° amplitudes had a higher AUC than the PERG-ratio, we used only the PERG 0.8° amplitudes for the below analysis. As a measure of structural damage in glaucoma, mean pRNFL was also statistically different between groups (ANOVA; P<0.0125 = 0.000042), it was significantly reduced in GLA_s and GLA_G vs controls (T-test; P<0.05 = 0.012 and P<0.025 = 0.00002, respectively; Figure 5.E)

3.4. Correlation of PhNR/b-wave ratio and PERG 0.8° amplitude to VF MD, pRNFL thickness, and age
Finally, we tested the correlation of mfPhNR/b-wave ratio with other measures of retinal ganglion cell integrity, i.e. PERG 0.8°, pRNFL and VF-MD. All correlations were significant as detailed in Figure 6. Stepwise linear regression was conducted to identify the measure of ganglion cell integrity predicts the mfPhNR/b-wave ratio best. This analysis indicated pRNFL [t (48) = 4, P = 0.0002] as a single significant predictor for VF_SUM mfPhNR/b-wave ratio. Finally, we applied the same analysis steps to PERG 0.8 amplitudes. Significant correlations were found with all other structural and functional measures of retinal ganglion cell integrity, i.e. mfPhNR/b-wave ratio, pRNFL and MD. Again, stepwise linear regression indicated pRNFL [t (48) = 3.4, P = 0.001] as a single significant predictor for PERG 0.8° amplitude.

4. DISCUSSION

4.1. Summary of findings

We assessed the effect of stimulus timing on mfPhNR recordings for glaucoma detection and compared a set of conditions with different stimulation rates. Analyzing the mfPhNR/b-wave ratio, we found the best discrimination performance between controls and glaucoma suspects for the fastest stimulation condition, i.e., C_Fast_1. A spatially resolved analysis of the multifocal responses rendered the analysis of the summed responses of all visual field locations (VF_SUM) preferable and the central responses least effective. A subsequent detailed assessment of the diagnostic potential of VF_SUM mfPhNR/b-wave ratio for C_Fast_1 revealed a similar potential as PERG, pRNFL and VF-MD to differentiate between Controls and both glaucoma suspects and patients with glaucoma, i.e., GLAS and GLAG, respectively.

4.2. Comparisons between stimulation conditions

Our comparative approach was motivated by a variety of previous mfPhNR studies on glaucoma detection, that applied using slow (by inserting around 30 frames(Rajagopalan et al. 2014)) or fast sequences (1-9 frames(Kaneko et al. 2015; Kato et al. 2015; Tanaka et al. 2020)). Our study suggests advantages of the faster stimulation protocol (i.e. mfPhNR/b-wave ratio C_Fast_1) in the early detection of glaucoma, as it performed better than the other conditions tested for the discrimination GLAS from controls. Additionally, it should be noted that C_Fast_1 is the condition with the shortest recordings time (at equal m-sequence length for all
conditions), i.e. 1 minute and 1 second, which bears the potential to increase signal-to-noise and possibly discriminative power further by increasing recording time.

4.3. **Topographical comparisons of PhNR/b-wave ratio of C\textsubscript{Fast 1}**

In the present study, mfPhNR/b-wave ratio of C\textsubscript{Fast 1} remained unaltered in the central area for both patients’ groups (GLAs and GLAG), compared to a decreased response in peripheral visual field locations. Previous studies reported reduced central retinal responses and unaltered peripheral mfPhNR/b-wave ratios in glaucoma (Viswanathan et al. 2001; Kaneko et al. 2015; Kato et al. 2015). Recently the mfPhNR/b-wave ratio was reported (Tanaka et al. 2020) to be significantly different in all visual field locations, i.e., both central and peripheral responses in glaucoma patients [range of perimetric damage mean deviation[dB]: -29.26 – 2.02]. This might be related to methodological discrepancies between the studies possibly with diverging sensitivities to different damage sites.

4.4. **PhNR ratio AUCs for GLAS and GLAG**

We obtained, based on the mfPhNR/b-wave ratio, similar AUCs for GLAS and GLAG (AUCs: 0.84 and 0.78, respectively). These AUCs correspond well to those of previous studies employing conventional or focal recordings schemes, e.g. Preiser et al. (Preiser et al. 2013) (AUC = 0.80), Machida et al (Machida et al. 2010) (AUC = 0.89 to 0.97 for early and late glaucoma, respectively), Kirkiewicz et al. (AUC = 0.78 and 0.86, for moderate and advanced glaucoma, respectively) (Kirkiewicz et al. 2016).

4.5. **PhNR ratio AUCs comparisons across diagnostic modalities**

In our cross-modal comparison, we demonstrated similar AUCs for mfPhNR/b-wave ratio and PERG amplitude (at 0.8° checksize), pRNFL and PERG ratio for GLAS as well as GLAG. This is in accordance with Preiser et al. (Preiser et al. 2013) who reported AUCs based on the conventional PhNR/b-wave ratios and the PERG ratio to be comparable for preperimetric (AUCs: 0.80 and 0.73, respectively) and manifest glaucoma (AUCs: 0.80 and 0.79, respectively). By comparison of AUCs of conventional PhNR measures to those of other approaches assessing optic nerve integrity (Kirkiewicz et al. 2016), it was concluded that the conventional PhNR is equivalent to other diagnostic tests in different stages of glaucoma. We consider,
therefore, for both conventional and multifocal recording modes, the PhNR/b-wave ratio as a useful measure in glaucoma diagnostics, specifically as it requires no clear media and refraction.

4.6. PhNR ratio association with other structural and functional measures

A correlation of PhNR and PERG measures in glaucoma has previously not been reported (Preiser et al. 2013). In our present study, we observed mfPhNR/b-wave ratios to be significantly correlated with both PERG 0.8° amplitude and PERG ratio ($r^2 = 0.11$, $P = 0.02$). This supports the view that both measures they reflect similar damage sites and mechanisms, which is further corroborated by the cross-modal correlations of the electrophysiological measures with functional and anatomical measures we observed in accordance with previous conventional PhNR studies (Viswanathan et al. 2001; Machida et al. 2008; Kirkiewicz et al. 2016), PERG studies (Parisi et al. 2001; Toffoli et al. 2002; Elgohary et al. 2019) and another mfPhNR study (Kato et al. 2015). In fact, the observed pRNFL changes were a predictor for both mfPhNR/b-wave ratio and PERG 0.8° amplitude.

5. CONCLUSION

We have shown that mfPhNR/b-wave ratio of C_{FAST_1} is complementary in glaucoma diagnosis and found to have equivalent diagnostic accuracy as compared to other established functional and structural methods and might be superior in eyes classified to have normal optic disc (i.e., GLA5). These findings open doors to standardizing mfPhNR recording, testing in longitudinal studies with larger sample size and translating them in glaucoma diagnostics.
Acknowledgements

This work was supported by European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement (No. 675033) to Michael B. Hoffmann.

Conflict of interest statement – None
REFERENCES


Elghohary AM, Elbedewy HA, Saad HA, Eid TM. Pattern electroretinogram changes in patients with primary open-angle glaucoma in correlation with visual field and optical coherence tomography changes. Eur J Ophthal mol. 2019 Sep 9;1120672119872606.


FIGURE LEGENDS

**Figure 1** Schematic of the mfPhNR stimulation paradigm. The multifocal stimulus array consisted of 5 visual field locations with inner diameter of 5° and outer of 24° and a small fixation cross in the center. Stimulation followed an m sequence with $2^9$-1 elements, i.e., 511 stimulated patterns of black and white combinations. For the fast sequence protocol (C\textsubscript{Fast,1}) each elements lasted for 9 frames, as depicted.

**Figure 2** Comparisons of AUCs ± SE for mfPhNR amplitudes (left) and mfPhNR/b-wave ratio (right) for the discrimination between controls vs glaucoma suspects (GLA\textsubscript{S}) and glaucoma (GLA\textsubscript{G}) across a range of stimulations conditions C\textsubscript{Slow,3} (i.e., slowest condition with 25 dark frames and 5 bright flashes) to C\textsubscript{Fast,1} (i.e., fastest condition with 8 dark frames and 1 bright flash). While for the mfPhNR amplitudes AUCs did not differ significantly, for the mfPhNR/b-wave ratio AUCs for C\textsubscript{Fast,1} exceeded those for C\textsubscript{Slow,1} ($P = 0.02$).

**Figure 3** Grand mean average traces of mfPhNR ("VF\textsubscript{SUM} trace"; A; amplitudes of responses are referenced to the baseline) and trace arrays (B) for controls, glaucoma suspects (GLA\textsubscript{S}) and glaucoma (GLA\textsubscript{G}) of the fastest condition responses (C\textsubscript{Fast,1}).

**Figure 4** Comparison of mfPhNR/b-wave ratio of the fastest condition across groups and topographic comparisons. Corrected alpha threshold is 0.025 for the more significant P value in each plot. mfPhNR/b-wave ratio is significantly different in all visual field locations across groups except for the center (for P values see panels). Controls' mfPhNR/b-wave ratio was significantly different vs either group, i.e., glaucoma suspects and glaucoma group. Box: 25%-75% interquartile range; horizontal line is the median value and the whiskers represent the range.

**Figure 5.** A AUC ± SE comparison between diagnostic modalities [i.e., mfPhNR/b-wave ratio of fastest condition C\textsubscript{Fast,1}, pattern electroretinogram (PERG) 0.8° amplitude, PERG ratio and peripapillary retinal nerve fiber layer thickness (pRNFL)] across groups. There were no significant differences of AUCs across modalities after
multiple testing correction. Blue= glaucoma suspect (GLAs), Red: Glaucoma group (GLAs).

**B-E** Comparisons of mfPhNR/b-wave ratio, PERG 0.8° amplitude, PERG ratio, and pRNFL across controls, glaucoma suspect and glaucoma group. ANOVA showed significant differences across groups (P values as indicated in the panels). Post-hoc analysis showed significant differences between control vs glaucoma suspect and control vs glaucoma (P values as indicated in the panels). Post hoc analysis corrected alpha value is 0.025 for the more significant P value in each plot. Box: 25%-75% interquartile range; horizontal line is the median value and the whiskers represent the range. Y-axis specified the diagnostic modality as indicated in the panel title.

**Figure 6.A** Correlation plots between mfPhNR/b-wave ratio fastest condition (CFast_1) and visual field mean deviation (VF-MD), peripapillary retinal nerve fiber layer thickness (pRNFL) & pattern electroretinogram (PERG) 0.8° amplitude. There were significant association between mfPhNR/b-wave ratio and the above-mentioned measures in which VF-MD, pRNFL and PERG 0.8° amplitude explained 14%, 26% and 11% of mfPhNR/b-wave ratio variance, respectively (see text).

**B-Correlation plots** between PERG 0.8° amplitude and VF-MD, pRNFL and mfPhNR/b-wave ratio. There were significant association between PERG 0.8° amplitude and the above-mentioned measures in which VF-MD, pRNFL and mfPhNR/b-wave ratio explained 16%, 19% and 11% PERG 0.8° amplitude, respectively (see text).
Table 1. Overview of participants’ characteristics

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>GLA&lt;sub&gt;S&lt;/sub&gt;</th>
<th>GLA&lt;sub&gt;G&lt;/sub&gt;</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age [years]</strong></td>
<td>52.12 ± 2.25</td>
<td>61.84 ± 1.79</td>
<td>57.90 ± 3.73</td>
<td>0.080</td>
</tr>
<tr>
<td><strong>BCVA [decimal]</strong></td>
<td>1.11 ± 0.04</td>
<td>1.73 ± 0.70</td>
<td>0.99 ± 0.04</td>
<td>0.172</td>
</tr>
<tr>
<td><strong>VF-MD [dB]</strong></td>
<td>0.74 ± 0.19</td>
<td>2.12 ± 0.34</td>
<td>4.44 ± 1.07</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td><strong>VF-PSD [dB]</strong></td>
<td>4.9 ± 0.75</td>
<td>9.18 ± 1.22</td>
<td>32.31 ± 7.85</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

*ANOVA test.

GLA<sub>S</sub> = Glaucoma suspects; GLA<sub>G</sub> = Glaucoma group; BCVA = Best-corrected visual acuity in decimal; VF-MD = visual field mean deviations, VF-PSD = visual field pattern standard deviations.

Table 2. Paired t-test comparisons of mfPhNR amplitudes and ratio of C<sub>Fast_1</sub> vs. other stimulation condition in controls

<table>
<thead>
<tr>
<th></th>
<th>C&lt;sub&gt;Fast_1&lt;/sub&gt; Mean ± SEM</th>
<th>vs. others Mean ± SEM</th>
<th>difference Mean ± SEM</th>
<th>t(23)</th>
<th>P* value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>mfPhNR Amplitude</strong></td>
<td>-9.86 ±0.52</td>
<td>C&lt;sub&gt;Slow_3&lt;/sub&gt; -10.63 ±1.06</td>
<td>0.77 ±1.03</td>
<td>0.75</td>
<td>0.46</td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;Slow_2&lt;/sub&gt; -11.62 ±0.63</td>
<td>1.76 ±0.47</td>
<td>3.76</td>
<td>0.004</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;Slow_1&lt;/sub&gt; -11.31 ±0.52</td>
<td>1.45 ±0.39</td>
<td>3.76</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;Fast_3&lt;/sub&gt; -9.21 ±0.89</td>
<td>-0.65 ±0.82</td>
<td>-0.80</td>
<td>0.43</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;Fast_2&lt;/sub&gt; -9.16 ±0.61</td>
<td>-0.70 ±0.39</td>
<td>-1.80</td>
<td>0.09</td>
<td></td>
</tr>
<tr>
<td><strong>mfPhNR/b-wave Ratio</strong></td>
<td>0.41 ±0.02</td>
<td>C&lt;sub&gt;Slow_3&lt;/sub&gt; 0.75 ±0.08</td>
<td>-0.33 ±0.08</td>
<td>-4.25</td>
<td>0.0009</td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;Slow_2&lt;/sub&gt; 0.64 ±0.04</td>
<td>-0.23 ±0.03</td>
<td>-8.13</td>
<td>&lt; 0.00001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;Slow_1&lt;/sub&gt; 0.51 ±0.03</td>
<td>-0.10 ±0.02</td>
<td>-5.88</td>
<td>0.00001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;Fast_3&lt;/sub&gt; 0.58 ±0.06</td>
<td>-0.17 ±0.06</td>
<td>-2.89</td>
<td>0.016</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;Fast_2&lt;/sub&gt; 0.46 ±0.03</td>
<td>-0.05 ±0.02</td>
<td>-2.19</td>
<td>0.039</td>
<td></td>
</tr>
</tbody>
</table>

mfPhNR: multifocal photopic negative response; C<sub>Fast_1</sub>, C<sub>Fast_2</sub>, C<sub>Fast_3</sub> (fast stimulation conditions with 1, 2, 5 bright and 8 dark frames, respectively); C<sub>Slow_1</sub>, C<sub>Slow_2</sub>, C<sub>Slow_3</sub> (slow stimulation conditions with 1, 2, 5 bright and 25 dark frames, respectively); SEM: standard error of mean; *Paired t-test P value corrected for multiple testings.
Figure 1

9 frames: $2^3-1$ m-Sequence with base period of 9 frames (120 ms)

Bright

200 cd/m$^2$

Dark

7 cd/m$^2$

Flashes
Figure 2

AUC ±SE comparisons between controls and patients' groups across stimulations conditions

mIPhNR Amplitude

mfPhNR/b-wave ratio
Figure 3

A

B

- Controls
- GLA_S
- GLA_G

Amplitude (µV)

Time [ms]

-10.8µV/20ms
24µV/38.3ms
-7.4µV/75.8ms
-11.3µV/20ms
-7.2µV/75.8ms
-12.6µV/20ms

-10
-20
-30
0
10
20
30

-30
-20
-10
0
10
20
30

0 20 40 60 80 100

Time [ms]

-12.6µV/20ms
24µV/38.3ms
-7.4µV/75.8ms
-10.8µV/20ms
-7.4µV/75.8ms

2µV

100 ms
<table>
<thead>
<tr>
<th>Figure 4</th>
<th>A. Center</th>
<th>B. Periphery</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ANOVA, $P_{0.05} = 0.65$</td>
<td>ANOVA, $P_{0.05} = 0.0013$</td>
</tr>
<tr>
<td></td>
<td>0.402 0.819</td>
<td>0.003 0.000935</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. Nasal hemifield</td>
<td>ANOVA, $P_{0.05} = 0.0013$</td>
<td>ANOVA, $P_{0.05} = 0.0012$</td>
</tr>
<tr>
<td></td>
<td>0.014 0.000457</td>
<td>0.002 0.009</td>
</tr>
<tr>
<td>D. Temporal hemifield</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E. Upper hemifield</td>
<td>ANOVA, $P_{0.05} = 0.0023$</td>
<td>ANOVA, $P_{0.05} = 0.00045$</td>
</tr>
<tr>
<td></td>
<td>0.027 0.002</td>
<td>0.000809 0.002</td>
</tr>
<tr>
<td>F. Lower hemifield</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G. Summed response</td>
<td>ANOVA, $P_{0.05} = 0.00027$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.001 0.001</td>
<td></td>
</tr>
</tbody>
</table>

Control  GLAₜ  GLAₙ
Figure 5

A. Auc ± SE compares across diagnostic modalities

B. PhNR/β-wave ratio

C. PERG .8” amplitude [μV]

D. PERG ratio

E. pRNFL [μm]
Figure 6